Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide plus basal insulin after switch from premixed insulin in inadequately controlled type 2 diabetes
2013-005334-37Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lixisenatide and insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Medical University of Vienna. Primary endpoint: Change in HbA1c. Started May 2014; status: completed.
02
Drugs
lixisenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-005334-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005334-37.